Mitsubishi UFJ Asset Management Co. Ltd. Purchases 9,393 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 94,698 shares of the biopharmaceutical company's stock after purchasing an additional 9,393 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.07% of Alnylam Pharmaceuticals worth $22,186,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Larson Financial Group LLC increased its position in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 73 shares in the last quarter. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. True Wealth Design LLC increased its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 153 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $35,000. Finally, Versant Capital Management Inc lifted its holdings in shares of Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 83 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of analysts have commented on the stock. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday. Royal Bank of Canada upped their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a report on Friday, March 21st. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Wells Fargo & Company increased their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research note on Friday, March 21st. Finally, Citigroup raised their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $316.25.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock traded down $26.42 on Friday, reaching $235.74. 1,881,579 shares of the company traded hands, compared to its average volume of 842,696. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm has a market capitalization of $30.67 billion, a PE ratio of -108.64 and a beta of 0.30. The company has a 50 day moving average of $259.03 and a 200 day moving average of $260.33. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares of the company's stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.